ACC会议共识： 他汀类药物仍然是一线用药

fadi99

CHICAGO — The ENHANCE study was presented at the American College of Cardiology's 57th Annual Scientific Session on Sunday, March 30, and published online in the New England Journal of Medicine, comparing the effect on carotid artery thickening of simvastatin alone versus simvastatin plus ezetimibe in patients with a genetic condition that causes severe increases in serum cholesterol. While some of these data had been released previously, a complete peer-reviewed presentation had not been available. These reports have resulted in extensive media coverage on the findings.
芝加哥－－3月30日，周日，美国心脏病学会（ACC）第57届年会上公布了ENHANCE研究的结果，同时发表在《新英格兰医学杂志》（New England Journal of Medicine）上，ENHANCE研究是在遗传性高胆固醇血症患者中对比单独应用辛伐他汀和联用辛伐他汀与依折麦布对颈动脉内膜中层厚度的影响。虽然一些研究数据先前已经公布，但是尚无完全的同行评议。这个报告已经引起了广大媒体的关注。

The study reinforces the need to adhere to current American College of Cardiology/American Heart Association Guidelines which recommend statins to the maximally tolerated dose or to goal as first line treatment for patients with coronary artery disease. The data from the ENHANCE study should be considered as the NHLBI guidelines writing group is working on their update of the national cholesterol treatment guidelines in the coming months.
这个研究进一步强化了美国心脏病学会、美国心脏协会的指南内容：对冠心病患者推荐将他汀类药物作为一线治疗用至最大耐受剂量或血脂达标。正致力于编写并即将出台国家胆固醇治疗更新指南的国家心肺与血液研究所（NHLBI）指南写作组的专家们应当会考虑ENHANCE研究的相关数据。

Patients should speak with their physician before discontinuing any therapy.
患者中断任何治疗前应当详细咨询医生。

ENHANCE研究简介
ENHANCE研究旨在揭示依折麦布与他汀联用在延缓和逆转颈动脉粥样硬化病变进展方面的疗效。研究者将720例杂合子家族性高胆固醇血症患者随机分入依折麦布10 mg联合辛伐他汀80 mg组,或单用辛伐他汀80 mg组。经2年治疗,结果显示,两组患者的主要终点——颈动脉内膜中层厚度(IMT)的平均改变无显著差异(联合组对单药组:0.0111 mm对0.0058 mm,P=0.29);心血管事件及治疗相关不良事件的发生率亦相近;联合组的低密度脂蛋白胆固醇(LDL-C)水平下降幅度显著高于单药组(58%对41%,P<0.01)。

相关报道：《ENHANCE研究阴性结果正式公布 权威人士建议坚持他汀一线治疗》
http://www.cmt.com.cn/article/080403/a080403c0402.htm